Fostamatinib for the Treatment of Hospitalized Adults With Coronavirus Disease 2019: A Randomized Trial is a research paper published in Clinical Infectious Diseases (2021). On theSindex it has a DataRank of 2.2. It has been cited 63 times, with 49 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.624
From this paper's citation signal
Citation Network Contribution
1.6
From 40 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 49 citers.
Division of Intramural Research (DIR) of the National Heart, Lung and Blood Institute
Cooperative Research and Development Agreement
National Institutes of Health
MeSH Terms
Keywords
Additional file 1 of Total network controllability analysis discovers explainable drugs for Covid-19 treatment
Additional file 1 of Total network controllability analysis discovers explainable drugs for Covid-19 treatment
Additional file 3 of Total network controllability analysis discovers explainable drugs for Covid-19 treatment
Additional file 2 of Total network controllability analysis discovers explainable drugs for Covid-19 treatment
Additional file 3 of Total network controllability analysis discovers explainable drugs for Covid-19 treatment
Additional file 2 of Total network controllability analysis discovers explainable drugs for Covid-19 treatment